# TRANSVISTA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transvista

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.transvista.com/
- Total disclosed funding: $14M
- Latest round: Series B (Feb 10, 2026)
- Investors on record: 17

## About

Founded in 2016 and based in Beijing, China, Beijing Chaoweijing Biotechnology Co., Ltd is a medical device manufacturing company that focuses on microscopy imaging systems and biomedical imaging equipment. Heping Cheng, the founder and chief scientist of the company, is a professor from Peking University. The company acquired 36 invention patents. It was recognized as the National High-tech Enterprise and National Specialized, Refined, Featured and Original SMEs. It cooperates with Peking Union Medical College Hospital, China-Japan Friendship Hospital, Peking University and other hospitals. It established the Beijing Biomedical Imaging Laboratory in collaboration with Peking University, Beihang University and other universities. In 2018, the company established a branch office in Nanjing. In February 2025, it closed a series B funding led by new investors Fosun Health Capital and Shenzhen Capital Group, with participation from other new investor JIC Investment.

The company's main business is the research and development of microimaging systems. Products include optical microscopy imaging systems, medical endoscope systems, and acoustic resolution imaging systems. It has served clients including New York University, Peking University, Shanghai Neurological Institute of Chinese Academy of Sciences, and Max Planck Institute.

The company generates revenue by providing optical microscopy imaging systems, miniaturized two-photon microscope and other biomedical equipment.

The company will use the funds for the research and development of scientific instruments and medical devices and the expansion of domestic and overseas markets.

## Funding rounds

- Series B, Feb 10, 2026, $14M — Zhongdian Shurong Investment Management, Shunxi Fund, Zhongguancun Science City Capital, Kaiheng Capital
- Series B, Feb 12, 2025 — JIC Investment, Shenzhen Capital Group, Fosun Health Capital
- Series A, Dec 29, 2023 — China Capital Management, BICI Capital Fortune, Shouzheng Zefu Innovation Investment (Beijing), Xietong Investment, Stellar River Capital Managemet, Guangdong Xietong Holding
- Series A, Apr 9, 2019 — JC Capital, Shenzhen Guozhong Venture Capital
- Angel, Feb 24, 2017 — SYN Capital, Casstar Capital

## Investors

- SYN Capital — Angel
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel
- JC Capital (https://capitalatlas.ai/funds/jc-capital) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series A
- BICI Capital Fortune (https://capitalatlas.ai/funds/bici-capital-fortune) — Series A
- Shouzheng Zefu Innovation Investment (Beijing) — Series A
- Xietong Investment — Series A
- Stellar River Capital Managemet — Series A
- Guangdong Xietong Holding — Series A
- JIC Investment — Series B
- Shenzhen Capital Group — Series B
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series B
- Zhongdian Shurong Investment Management (https://capitalatlas.ai/funds/zhongdian-shurong-investment-management) — Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series B
- Kaiheng Capital (https://capitalatlas.ai/funds/kaiheng-capital) — Series B